{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98"}]}],"title":"Week 48 response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93"}]}],"title":"Week 96 response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"89"}]}],"title":"Week 144 response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85"}]}],"title":"Week 192 response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79"}]}],"title":"Week 264 response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}],"title":"Week 312 (Year 6) response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71"}]}],"title":"Week 360 (Year 7) response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}],"title":"Week 408 (year 8) response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}],"title":"Week 468 (year 9) response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}],"title":"Week 528 (year 10) response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"description":"This outcome measure was the number of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MMR data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point.","groups":[{"description":"Participants who completed the nilotinib treatment consolidation (NTCS) phase and maintained major molecular response entered the treatment-free remission (TFR) phase. During the TFR phase, nilotinib treatment was discontinued and participants were monitored regularly for molecular response.","id":"OG000","title":"TFR Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis set (FAS) included all participants who completed 52 weeks of nilotinib treatment in the NTCS phase and subsequently entered the TFR phase","reportingStatus":"POSTED","timeFrame":"Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10","title":"Number of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase","type":"SECONDARY","unitOfMeasure":"Participants"}